The first federal bellwether in the preterm infant formula multidistrict litigation to reach a jury ended in a defense verdict for Mead Johnson.
For plaintiff firms, the result raises an important question beyond the verdict itself:
What separates a recognizable NEC claim from a case that warrants continued legal and medical review?
On August 31, 2026, a federal jury in the Northern District of Illinois returned a unanimous verdict for Mead Johnson in Inman v. Mead Johnson & Company. The case involved allegations that Enfamil Premature formula caused a premature infant to develop necrotizing enterocolitis, or NEC, and that Mead Johnson failed to adequately warn healthcare providers about the alleged risk.
The jury ultimately concluded that the formula did not cause the infant’s NEC.
What makes Inman particularly instructive is that the case had already cleared significant pretrial hurdles. The plaintiff’s specific-causation expert survived a Daubert challenge, and Mead Johnson’s motion for summary judgment was denied as to Mead Johnson & Company.
The case reached a jury.
Mead Johnson still prevailed.
For plaintiff firms, that distinction highlights an important consideration in NEC litigation: surviving pretrial challenges and persuading a jury are not the same standard.
Start With the Individual Medical Record
At the initial intake stage, three facts may identify a potential NEC claim:
- Premature birth
- Cow’s-milk-based preterm formula exposure
- NEC diagnosis
But those facts alone may not provide enough information to understand the circumstances of an individual case.
The medical history in Inman demonstrates why.
Daniel Windley was born at 29 weeks and weighed 670 grams. According to the court’s description of the medical record, the pregnancy involved severe selective fetal growth restriction, twin-to-twin transfusion syndrome and maternal Rh alloimmunization. Daniel was also anemic and received multiple blood transfusions before and after birth.
Those circumstances do not independently establish or defeat causation. They do demonstrate how complex the medical history of an extremely premature infant can be.
For firms evaluating NEC cases, intake may need to capture more than whether an infant was premature. Relevant information can include:
- Gestational age
- Birth weight
- Multiple-birth status
- Fetal growth restriction
- Prenatal complications
- Significant NICU complications
- Blood transfusions
- Respiratory support
- Sepsis or suspected sepsis
- Other documented NEC risk factors
- Major congenital or genetic concerns
Understanding these individual circumstances earlier can help firms determine what additional medical and legal review may be appropriate.
Reconstruct the Feeding Timeline
Product exposure should also be evaluated as a chronology, rather than simply a yes-or-no intake question.
Daniel’s feeding history involved several different sources of nutrition.
According to the court’s summary of the medical record, he initially received donor human milk and later his mother’s milk, which was fortified with a cow’s-milk-based fortifier. During an investigation for possible galactosemia, he received Pregestimil and Nutramigen. After testing ruled out galactosemia, he returned to fortified mother’s milk.
On June 6, his feeding regimen changed to donor milk combined with Enfamil Premature. Beginning June 11, he received Enfamil Premature exclusively. His condition began deteriorating around June 18, and he died on June 23.
That chronology illustrates why simply confirming “Enfamil exposure” may leave important questions unanswered.
A more developed intake process can capture:
- Exact formula product
- Date of first administration
- Frequency and duration of use
- Human-milk exposure
- Cow’s-milk-based fortifier exposure
- Other formulas administered
- Transition to predominant or exclusive formula feeding
- Initial gastrointestinal or clinical symptoms
- Date NEC was suspected
- Date NEC was diagnosed
- Feeding changes preceding deterioration
The objective is not to determine causation during intake. It is to collect enough information to identify when an individual case may warrant deeper medical and legal review.
Product Identification Matters
For initial intake, identifying Enfamil or Similac exposure may provide a useful starting point.
For further case evaluation, greater specificity may matter.
Inman involved Enfamil Premature Formula, rather than an unspecified Enfamil product. The plaintiff also advanced a specific design theory concerning the formula’s carbohydrate composition and a proposed lactose-based alternative.
Product-liability theories can depend on the manufacturer, product, formulation, timing of exposure and theory being asserted.
When available, firms may want to capture:
- Manufacturer
- Exact product name
- Formula type
- Caloric concentration
- Powder or ready-to-feed formulation
- Hospital or NICU where administered
- Dates of administration
- Feeding and nutrition records
- Lot information
- Photographs or retained packaging
A broad product-exposure question can help identify a potential claim. It should not necessarily be the final step in understanding the relevant product history.
Specific Causation Deserves Separate Review
One of the most significant lessons from Inman comes from what happened before trial.
The plaintiff’s specific-causation expert reviewed Daniel’s medical history and performed a differential etiology addressing potential alternative causes and contributing factors. The court permitted that testimony to proceed.
The jury nevertheless found for Mead Johnson.
That distinction matters because admissible causation testimony does not necessarily translate into persuasive causation evidence at trial.
For plaintiff firms, case review may therefore need to evaluate the individual causation record separately from the broader scientific questions underlying the litigation.
Questions may include:
- How close was the relevant formula exposure to NEC onset?
- What alternative explanations appear in the medical record?
- What was the infant’s medical condition before the relevant exposure?
- Did symptoms follow a significant feeding change?
- What did treating physicians document?
- Are there infectious, ischemic, congenital or other competing explanations?
- Is the medical chronology internally consistent?
- Are the records necessary to evaluate these questions available?
These issues can be especially important in cases involving extremely premature infants with complicated NICU histories.
Treating Providers Can Shape Failure-to-Warn Claims
The healthcare-provider record can also become significant.
Before trial, the court permitted the Inman failure-to-warn theory to proceed because factual disputes remained concerning what Daniel’s providers understood about formula-related NEC risk and how Mead Johnson’s communications may have affected those understandings.
The record also contained disputes concerning the hospital’s feeding protocol, why Daniel transitioned to formula, and the role clinicians played in those decisions.
That makes provider evidence relevant well before deposition preparation.
During case evaluation and record collection, firms may want to determine:
- Who selected the feeding regimen?
- Why was formula selected?
- Were mother’s milk or donor milk available?
- Did a NICU feeding protocol influence the decision?
- What did clinicians understand about NEC risk?
- Could different warning information have affected the feeding decision?
- What do treating-provider records indicate about the alleged causal relationship?
These questions can help firms develop a more complete understanding of the individual circumstances surrounding a potential claim.
General Causation and Individual Causation Are Different Questions
Mass tort litigation often involves scientific evidence relevant across a larger group of cases.
Individual claims still depend heavily on individual medical and factual records.
That distinction is particularly important following Inman.
The federal MDL court previously permitted general-causation evidence concerning the relationship between cow’s-milk-based formula and NEC to proceed. The Inman plaintiff also presented case-specific expert testimony that survived pretrial challenges.
The jury nevertheless found that Enfamil did not cause Daniel’s NEC.
For firms reviewing potential cases, that creates two separate questions:
Does the broader litigation support a viable general-causation theory?
And:
Does this particular infant’s medical and exposure history provide sufficient information for continued case-specific review?
Those questions may require different evaluation checkpoints.
Earlier Federal Bellwethers Point to the Same Issue
Inman was the fourth case in the MDL’s initial bellwether group.
The three previous federal bellwether cases involved Abbott’s Similac Special Care product and ended at summary judgment without reaching a jury.
Inman moved beyond that stage and still resulted in a defense verdict.
For plaintiff firms, the progression illustrates several distinct levels of case development:
Potential claim → medical and exposure review → expert review → pretrial evaluation → trial
Each stage can raise different factual, medical and legal questions.
An intake process focused only on basic exposure and injury criteria may not capture the full medical history and individual circumstances necessary for meaningful case review.
A More Structured NEC Qualification Framework
Rather than treating every premature-infant NEC case involving formula exposure the same way, firms may benefit from a layered review process.
1. Product Exposure
Confirm, when available:
- Manufacturer
- Exact product
- Hospital or NICU administration
- Dates and duration of use
- Feeding and nutrition records
2. Medical History
Document:
- Gestational age
- Birth weight
- NEC diagnosis
- NEC severity
- Surgical intervention or bowel resection
- Significant neonatal complications
- Relevant medical history
3. Feeding and Causation Timeline
Map:
- Human-milk exposure
- Donor-milk exposure
- Fortifier exposure
- Formula exposure
- Transition to predominant or exclusive formula
- Symptom onset
- NEC diagnosis
4. Alternative Risk Factors
Identify documented:
- Sepsis
- Severe growth restriction
- Blood transfusions
- Hypoxic or ischemic events
- Congenital conditions
- Other significant neonatal complications
The presence of these factors does not independently establish or rule out causation. Identifying them can help ensure that the infant’s complete medical history is considered during further review.
5. Provider and Warning Evidence
Determine:
- Who selected the feeding regimen
- Why formula was selected
- Whether alternatives were available
- Whether a NICU feeding protocol influenced the decision
- What providers documented concerning NEC risk
- Whether different warning information could have affected the feeding decision
6. Records Readiness
Determine whether relevant records are available or obtainable, including:
- Complete NICU records
- Feeding flow sheets
- Nutrition notes
- Radiology
- Operative reports
- Pathology
- Product documentation
- Treating-provider records
The goal is not to turn intake teams into medical experts or make causation determinations during intake.
It is to ensure that the individual medical history and circumstances surrounding each potential case are captured so attorneys and appropriate medical professionals can conduct a more informed review.
What the Mead Johnson Verdict Does and Does Not Mean
The August 31 verdict is significant, but it does not decide the remaining NEC litigation.
Bellwether trials are intended to provide information about issues that may recur across broader litigation, but each plaintiff’s case remains dependent on its own facts and evidence.
More than 800 cases were centralized in the federal MDL when the Inman verdict was reported, in addition to litigation proceeding in state courts.
The first federal NEC bellwether to reach a jury therefore provides an important development in the litigation, rather than a final answer about the remaining cases.
For plaintiff firms, one of its clearest operational lessons may be the importance of thoughtful, case-specific review.
Premature birth, formula exposure and an NEC diagnosis can identify a potential claim. Further evaluation may require considerably more:
- Precise product identification
- A detailed feeding chronology
- Complete prematurity and NICU history
- Consideration of other documented medical risk factors
- Timing between relevant exposure and NEC onset
- Treating-provider and warning evidence
- Complete medical and nutrition records
- Individualized legal and medical review
The Inman verdict does not determine whether another infant’s circumstances support a viable claim.
It does reinforce the importance of understanding the individual medical history, product exposure and circumstances of each case before drawing broader conclusions.
As NEC litigation continues to develop, firms may be better equipped to identify which cases warrant additional investigation and legal or medical review when these details are captured earlier in the process.
How SmashOrbit Legal Supports More Informed NEC Intake
As NEC litigation continues to develop, plaintiff firms may need to refine their intake criteria alongside new court rulings, bellwether results and emerging case-specific considerations.
At SmashOrbit Legal, we help plaintiff firms translate litigation developments into thoughtful acquisition and intake strategies, including qualification criteria designed to capture the medical, exposure and case-specific information firms need for further review.
The goal is not simply to generate inquiries. It is to help firms build intake processes that collect meaningful information while recognizing the individual circumstances behind every potential case.
As the litigation develops, intake criteria should develop with it.